Lexicon Pharmaceuticals (NASDAQ:LXRX) lost ~39% in the morning hours on Friday following a trading halt in the previous session as an FDA advisory committee declined to endorse its diabetes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback